This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Epidermal growth factor receptor (EGFR); HER2 (EGFR2; ERBB2; neu)	<p>Mouse and cell culture studies identified pyrrolo[3,2-<i>d</i>]pyrimidine-based dual inhibitors of HER2 and EGFR that could help treat cancer. In an EGFR- and HER2-expressing human breast cancer cell line, the lead inhibitor caused 50% growth decrease at 2 nM compared with baseline. In mouse xenograft models of HER2-overexpressing gastric cancer and EGFR-overexpressing head and neck cancer, the inhibitor caused tumor regression, whereas vehicle did not. Researchers did not disclose next steps, which could include evaluating the lead inhibitor in additional models of HER2- and EGFR-positive cancers.</p> <p>Takeda Pharmaceutical Co. Ltd. has the study's lead inhibitor in preclinical development to treat undisclosed cancers.</p> <p>SciBX 5(15); doi:10.1038/scibx.2012.386 Published online April 12, 2012</p>	Patent application filed; licensing status undisclosed	<p>Kawakita, Y. <i>et al. J. Med. Chem.</i>; published online March 22, 2012; doi:10.1021/jm300185p</p> <p>Contact: Tomoyasu Ishikawa, Takeda Pharmaceutical Co. Ltd., Kanagawa, Japan e-mail: ishikawa_tomoyasu@takeda.co.jp</p> <p>Contact: Youichi Kawakita, same affiliation as above e-mail: kawakita_youichi@takeda.co.jp</p>